Skip to main content

Table 8 Clinical and laboratory data of patients in organ transplant group during 2015–2018

From: Prevalence and clinical correlation of hepatitis E virus antibody in the patients’ serum samples from a tertiary care hospital in Thailand during 2015–2018

Characteristics Results
Number of organ transplant recipients n = 26 (26 out of 1,106; 2.35%)
Age (years) 39.5 (range 19–64)
Gender (Male) n = 17 (65.4%)
Type of organ transplantation  
 Kidney n = 14 (53.8%)
 Liver n = 8 (30.8%); due to HBV cirrhosis (n = 1), HCV cirrhosis with/without HCC (n = 3), autoimmune hepatitis (n = 1), Wilson disease (n = 2), cryptogenic cirrhosis (n = 1)
 Bone marrow n = 4 (15.4%)
Complications after transplantation  
 Graft rejection n = 6 (23.1%); kidney (n = 1), liver (n = 4), bone marrow (n = 1)
 Febrile neutropenia n = 3 (11.5%)
Clinical/laboratory presentations  
 Hyperbilirubinemia n = 6 (23.1%)
 Elevation of AST or ALT > 100 U/L n = 18 (69.2%)
Liver function test (All 26 cases)  
 AST (U/L) 125 (25–915)
 ALT (U/L) 243 (34–1,974)
 ALP (U/L) 193 (51–677)
 TB (mg/dL) 3.4 (0.3–35.4)
Timing of anti-HEV antibody test after organ transplantation  
 < 1 month n = 4 (15.4%)
 1 month – 1 year n = 4 (15.4%)
 > 1 year n = 18 (69.2%): 1–3 years (n = 8; 30.8%), 3–5 years (n = 4; 15.4%), 5–10 years (n = 6; 23.1%)
Results of anti-HEV antibody test  
 Positive anti-HEV IgG antibody n = 11 (42.3%)
 Positive anti-HEV IgM antibody n = 10 (38.5%)
Liver function test (each group) Anti-HEV serological statuses
  IgG-/IgM- (n = 11) IgG + /IgM- (n = 5) IgG-/IgM + (n = 4) IgG + /IgM + (n = 6)
AST (U/L) 51 (28–133) 102.5 (25–474) 136 (56–915) 55 (33–117)
ALT (U/L) 119 (34–455) 156 (81–301) 251.5 (152–1974) 108 (53–386)
ALP (U/L) 178 (62–677) 150.5 (102–333) 179 (67–348) 95 (51–134)
TB (mg/dL) 1.1(0.4–35.4) 1.5 (0.5–27.6) 0.8 (0.6–2.3) 0.5 (0.3–0.7)
  1. General patient information of 26 organ transplant recipients, including age, gender, clinical and laboratory presentation, type of organ transplantation, complications, anti-HEV antibody test timing, and anti-HEV antibody (IgG/IgM) detection rate, were demonstrated. Continuous variables were presented in median and range. Frequencies were presented in numbers and percentages. AST (aspartate aminotransferase enzyme), ALT (alanine aminotransferase enzyme), ALP (alkaline phosphatase enzyme), TB (total bilirubin), ESRD (end stage renal disease), HCC (hepatocellular carcinoma), HAV (hepatitis A virus), HBV (hepatitis B virus), HCV (hepatitis C virus), HEV (hepatitis E virus)